Real-world data suggests stopping immunotherapy after two years is reasonable in patients with advanced lung cancer
Over the past decade, the approval of immune checkpoint inhibitors has revolutionized treatment for patients with advanced lung cancer, helping many live longer lives and improving overall survival for the disease. However, ...